All News
Filter News
Found 808,690 articles
-
Patients Choice Laboratories Receives Accreditation From College of American Pathologists
9/6/2022
Patients Choice Laboratories announced that it has been awarded accreditation from the College of American Pathologists based on results of a recent on-site inspection as part of the CAP's Accreditation Programs.
-
Vor Bio to Participate in Upcoming September 2022 Investor Conferences
9/6/2022
Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.
-
Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases
9/6/2022
Valneva SE, a specialty vaccine company, announces that The Lancet Infectious Diseases, a peer-reviewed medical journal, has published the Company’s pivotal Phase 3 clinical data for its inactivated, whole-virus COVID-19 vaccine, VLA2001.
-
Theseus Pharmaceuticals to Participate at Upcoming September 2022 Investor Conferences
9/6/2022
Theseus Pharmaceuticals, Inc. announced that the company will participate in-person at the following upcoming investor conferences.
-
Business Intelligence Group Awards BioHarvest Sciences with the Prestigious Sustainability Leadership Award
9/6/2022
The Business Intelligence Group has named BioHarvest Sciences (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) as a winner of its 2022 Sustainability Leadership Award. The Business Intelligence Group seeks out and rewards those with vision, creativity and persistence, all hallmarks found in the world's leading companies and individuals across the globe. The awards programs rely on industry leaders who volunteer to read, score and judge nominations.
-
James Johnston named to Greyledge Technologies Board of Directors
9/6/2022
James Johnston, an innovative executive with extensive financial and strategic experience with global organizations, has joined the board of directors of Greyledge Technologies, Inc.
-
Celularity Announces Participation in Upcoming September 2022 Investor Conferences
9/6/2022
Celularity Inc. announced that Robert Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer of Celularity, will participate in fireside chats at the following investor conferences:
-
Pixium Vision announces participation in upcoming investor conferences in September 2022
9/6/2022
Pixium Vision SA, a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces that senior management will participate in the following investor conferences during September 2022:
-
Aravive to Participate in H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
Aravive, Inc. announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy Howard, Chief Financial Officer will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 at the Lotte New York Palace Hotel, New York, N.Y.
-
Appointment of Sachin Nanavati to PreveCeutical's Board of Directors
9/6/2022
PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces the appointment of Mr. Sachin Nanavati to the Company's board of directors (the "Board") effective September 1, 2022.
-
NKGen Biotech To Present SNK01 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2022
9/6/2022
NKGen Biotech, today announced that compassionate use cases of SNK01 + an immune checkpoint inhibitor in patients with advanced sarcoma have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) Annual Congress being held in Paris, France, September 9 – 13, 2022.
-
Selecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company’s Management will participate in a fireside chat and participate virtually in one-on-one investor meetings at the H.C. Wainwright 24th Annual Global Investment Conference.
-
Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences
9/6/2022
Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the company will be participating in two healthcare investment conferences next week in New York City.
-
ProPhase Labs to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)
9/6/2022
ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022 at 2:30 pm, Eastern Time.
-
TFF Pharmaceuticals to Participate at The H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that President and CEO Glenn Mattes will be participating in the H.C. Wainwright 24th Annual Global Investment Conference.
-
VYNE Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that David Domzalski, President and Chief Executive Officer of VYNE, is scheduled to participate at the H.C. Wainwright 24th Annual Global Investment Conference (Hybrid) on September 13, 2022.
-
Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
9/6/2022
Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the 24th Annual H.C. Wainwright Global Investment Conference.
-
LenioBio announces the appointment of Professor Daniel Bracewell to its Scientific Advisory Board
9/6/2022
LenioBio GmbH, today announced a strengthening of its Scientific Advisory Board with the appointment of Prof. Daniel Bracewell, Professor of Bioprocess Analysis at University College London's Department of Biological Engineering.
-
Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference
9/6/2022
Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that management will participate virtually in the hybrid in-person and virtual H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022.
-
Keros Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
9/6/2022
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), today announced that Jasbir S. Seehra, Ph.D, President and Chief Executive Officer, and Keith Regnante, Chief Financial Officer, will participate in a fireside chat presentation at the Morgan Stanley 20th Annual Global Healthcare Conference.